Clinical Trials

Oncoprex Monotherapy


Evaluating the Safety of Oncoprex as a Monotherapy

A phase I dose escalation trial was conducted at The University of Texas MD Anderson Cancer Center evaluating intravenous Oncoprex (TUSC2/FUS1) monotherapy in stage IV recurrent, metastatic lung cancer patients. The study showed for the first time that a tumor suppressor gene can be delivered intravenously and selectively to a patient’s cancer cells using a systemic nanovesicle vector, express high levels of mRNA and protein in cancer cells in both primary and distant metastatic tumor sites, alter relevant pathways in the cancer cell, and mediate clinically beneficial anti-cancer activity. Oncoprex was well tolerated with tumor responses noted in lung primary and metastatic tumors. The publication is available here.